Login to Your Account



Cymabay PBC drug gets go-ahead for longer dosing on positive phase II peek

By Michael Fitzhugh
Staff Writer

Monday, July 17, 2017

Cymabay Therapeutics Inc. said positive interim phase II results for its PBC treatment, seladelpar, won FDA support for extended dosing of the drug, a key go-ahead enabling the company to plan its phase III program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription